Pharmacokinetic considerations in seasonal malaria chemoprevention
African children under 5 years of age bear the main burden of global malaria mortality. Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) given monthly during the rainy season is a highly effective malaria intervention for children aged between 3 months...
| Príomhchruthaitheoirí: | , , |
|---|---|
| Formáid: | Journal article |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
Cell Press
2022
|
| _version_ | 1826309435460419584 |
|---|---|
| author | Chotsiri, P White, NJ Tarning, J |
| author_facet | Chotsiri, P White, NJ Tarning, J |
| author_sort | Chotsiri, P |
| collection | OXFORD |
| description | African children under 5 years of age bear the main burden of global malaria mortality. Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) given monthly during the rainy season is a highly effective malaria intervention for children aged between 3 months and 5 years living in the Sahel region, a region of intense but seasonal malaria transmission. This intervention is now being considered for other regions of Africa where malaria parasites are more drug resistant. Dihydroartemisinin-piperaquine (DP), an artemisinin-based combination therapy (ACT), has proved to be highly effective and well tolerated in intermittent preventive treatment in pregnant women and children. This combination may be a suitable alternative for SMC. Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing. |
| first_indexed | 2024-03-07T07:34:08Z |
| format | Journal article |
| id | oxford-uuid:e5d80787-377e-462c-83a4-f6b76032cca7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:34:08Z |
| publishDate | 2022 |
| publisher | Cell Press |
| record_format | dspace |
| spelling | oxford-uuid:e5d80787-377e-462c-83a4-f6b76032cca72023-02-20T11:28:15ZPharmacokinetic considerations in seasonal malaria chemopreventionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e5d80787-377e-462c-83a4-f6b76032cca7EnglishSymplectic ElementsCell Press2022Chotsiri, PWhite, NJTarning, JAfrican children under 5 years of age bear the main burden of global malaria mortality. Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) given monthly during the rainy season is a highly effective malaria intervention for children aged between 3 months and 5 years living in the Sahel region, a region of intense but seasonal malaria transmission. This intervention is now being considered for other regions of Africa where malaria parasites are more drug resistant. Dihydroartemisinin-piperaquine (DP), an artemisinin-based combination therapy (ACT), has proved to be highly effective and well tolerated in intermittent preventive treatment in pregnant women and children. This combination may be a suitable alternative for SMC. Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing. |
| spellingShingle | Chotsiri, P White, NJ Tarning, J Pharmacokinetic considerations in seasonal malaria chemoprevention |
| title | Pharmacokinetic considerations in seasonal malaria chemoprevention |
| title_full | Pharmacokinetic considerations in seasonal malaria chemoprevention |
| title_fullStr | Pharmacokinetic considerations in seasonal malaria chemoprevention |
| title_full_unstemmed | Pharmacokinetic considerations in seasonal malaria chemoprevention |
| title_short | Pharmacokinetic considerations in seasonal malaria chemoprevention |
| title_sort | pharmacokinetic considerations in seasonal malaria chemoprevention |
| work_keys_str_mv | AT chotsirip pharmacokineticconsiderationsinseasonalmalariachemoprevention AT whitenj pharmacokineticconsiderationsinseasonalmalariachemoprevention AT tarningj pharmacokineticconsiderationsinseasonalmalariachemoprevention |